This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Anavex To Present Corporate Update At BIO CEO & Investor Conference

Stock quotes in this article: AVXL

PALO ALTO, CA, Feb. 14, 2012 /PRNewswire/ - Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) today announced that Dr. George F. Tidmarsh, MD, PhD, Executive Director, is scheduled to present a corporate update at the BIO CEO & Investor Conference in New York. Dr. Tidmarsh's presentation will be webcast live and takes place on Tuesday, February 14, 2012, at 3:30 p.m. ET at the Waldorf-Astoria Hotel in New York City.

Dr. Tidmarsh plans to provide an update on the company's corporate strategy and progress in the clinical development of ANAVEX 2-73 for the treatment of Alzheimer's Disease (AD), which has successfully completed a Phase 1a clinical trial. Data published by world-renowned Alzheimer's Disease scientists shows that ANAVEZ 2-73 exhibits neuroprotective activity and reverses symptoms of AD in mouse models of the disease.  Phase 1a clinical data indicates that ANAVEX 2-73 is well tolerated with no dose-limiting toxicities unrelated to the drug's mechanism of action. ANAVEX 2-73 is the first of a new class of oral drugs being studied to potentially treat Alzheimer's through disease modification rather than symptomatic improvement alone.

The Anavex presentation will be webcast live at: http://www.veracast.com/webcasts/bio/ceoinvestor2012/36215125.cfm. Please register and log in approximately 10 minutes prior to the presentation to ensure a timely connection. The webcast replay will be available one hour after conclusion of the presentation and will be archived until May 14, 2012.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies.

About Alzheimer's Disease

While Alzheimer's Disease is most common in people over the age of 65, it can strike adults of any age irrespective of their gender, background or socioeconomic status. According to the Alzheimer's Association, an estimated 5.4 million Americans are currently living with Alzheimer's disease. The number of Americans aged 65 and over with Alzheimer's is estimated to reach 7.7 million in 2030. This represents a 50 percent increase from the 5.2 million Americans aged 65 and older who are currently affected. The Alzheimer's Association further projects that the number of Americans aged 65 and older who are affected by Alzheimer's disease may double or triple to between 11 and 16 million by 2050 unless there are developments to prevent or more effectively treat the disease.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs